Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Management tracks

    Regenerative medicine play Harvard Apparatus Regenerative Technology Inc. (NASDAQ:HART) said CEO David Green resigned. CFO Thomas McNaughton will be interim CEO.Vaccine developer Immunovaccine Inc. (TSX:IMV) named …

    Published on 4/17/2015
  • COMPANY NEWS: BMS transfers Erbitux rights to Lilly

    Bristol-Myers Squibb Co. (NYSE:BMY) will transfer to Eli Lilly and Co. (NYSE:LLY) full commercial rights for Erbitux cetuximab in the U.S., Canada and Puerto Rico. Erbitux is marketed as a monotherapy and in combination…

    Published on 4/16/2015
  • COMPANY NEWS: Levin takes lead at Ovid, strikes Lundbeck deal

    Newco Ovid Therapeutics Inc. (New York, N.Y.) said veteran dealmaker Jeremy Levin has taken the helm as CEO and in-licensed the biotech's first asset. The Orphan neurology play received exclusive, worldwide rights to …

    Published on 4/16/2015
  • COMPANY NEWS: Management tracks

    NIH said Jack Whitescarver will step down as director of its Office of AIDS Research, effective July 1. NIH will appoint an acting director to serve until a replacement is found.Merck KGaA (Xetra:MRK) named Alise Reicin…

    Published on 4/16/2015
  • COMPANY NEWS: District court denies another Amgen motion in biosimilars case

    The U.S. District Court for the Northern District of California denied a motion from Amgen Inc. (NASDAQ:AMGN) for a preliminary injunction pending appeal that would delay the launch of Zarxio filgrastim-sndz from the …

    Published on 4/15/2015
  • COMPANY NEWS: FDA approves Amgen's Corlanor for heart failure

    FDA granted marketing approval for Corlanor ivabradine from Amgen Inc. (NASDAQ:AMGN) to treat chronic heart failure. The selective If channel inhibitor will launch within one week at a wholesale acquisition price of $…

    Published on 4/15/2015
  • COMPANY NEWS: FDA panel backs Medicines Co.'s Kengreal

    FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-2 with one abstention to recommend approval of Kengreal cangrelor from The Medicines Co. (NASDAQ:MDCO) as an adjunct to percutaneous coronary intervention…

    Published on 4/15/2015
  • COMPANY NEWS: Management tracks

    Merck KGaA (Xetra:MRK) said Udit Batra will become head of its combined life sciences business, pending completion in mid-2015 of its planned acquisition of Sigma-Aldrich Corp. (NASDAQ:SIAL). Batra has been CEO and …

    Published on 4/15/2015
  • COMPANY NEWS: UC Berkeley seeks interference on Broad's CRISPR patents

    The University of California Berkeley filed a patent interference request with the U.S. Patent and Trademark Office (USPTO) related to 10 patents held by the Broad Institute of MIT and Harvard covering CRISPR-Cas9 (…

    Published on 4/15/2015
  • COMPANY NEWS: FDA panel backs label changes to DPP-4 inhibitors

    FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended on Tuesday that the agency add language about potential risks of heart failure to the labels of two DPP-4 inhibitors to treat diabetes -- Onglyza …

    Published on 4/14/2015
  • COMPANY NEWS: Lummy gains Chinese rights to Argos' AGS-003

    Argos Therapeutics Inc. (NASDAQ:ARGS) granted the Lummy Co. Ltd. subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. (SZSE:300006) development and commercialization rights in greater China for AGS-003 in oncology …

    Published on 4/14/2015
  • COMPANY NEWS: Management tracks

    Infectious disease play Eiger Biopharmaceuticals Inc. (San Carlos, Calif.) named Joanne Quan as CMO. Quan was VP of new product clinical development at InterMune Inc., which Roche (SIX:ROG; OTCQX:RHHBY) acquired.Drug …

    Published on 4/14/2015
  • COMPANY NEWS: USPTO declares interference in Tecfidera patent ruling

    Forward Pharma A/S (Copenhagen, Denmark) said an appeals board of the U.S. Patent and Trademark Office declared a patent interference and made Forward the senior party in a ruling concerning dimethyl fumarate (DMF), …

    Published on 4/14/2015
  • COMPANY NEWS: AZ partners with PatientsLikeMe for PRO data

    PatientsLikeMe Inc. (Cambridge, Mass.) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) access to its global network of patient-reported outcomes data concerning respiratory diseases, lupus, diabetes and oncology. AZ and …

    Published on 4/13/2015
  • COMPANY NEWS: Celgene buys stake in Mesoblast

    Mesoblast Ltd. (ASX:MSB; Pink:MBLTY) jumped A$0.78 (24%) to A$3.99 on Monday after Celgene Corp. (NASDAQ:CELG) made an A$58.4 million ($44.2 million) equity investment in the company.Celgene purchased 15.3 million …

    Published on 4/13/2015
  • COMPANY NEWS: Management tracks

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) hired Ramona Sequeira as president of its U.S. business unit. She succeeds Doug Cole, who stepped down March 31. Sequeira was VP of Lilly USA at Eli Lilly and Co. (NYSE:LLY).…

    Published on 4/13/2015
  • COMPANY NEWS: Roche acquires diagnostics play CAPP Medical

    Roche (SIX:ROG; OTCQX:RHHBY) acquired CAPP Medical (Palo Alto, Calif.), a genomics research company developing technology to detect and monitor circulating tumor DNA. Roche said the technology has the potential to aid …

    Published on 4/13/2015
  • COMPANY NEWS: EC extends label of Alexion's Soliris

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.31 to $182.68 on Friday after the European Commission approved an expanded label for Soliris eculizumab.Soliris' label now includes treatment of transfusion-naive …

    Published on 4/10/2015
  • COMPANY NEWS: Horizon's Actimmune gets Fast Track for Friedreich's

    Horizon Pharma plc (NASDAQ:HZNP) gained $1.16 to $28.48 on Friday after FDA granted Fast Track designation to Actimmune interferon (IFN) gamma-1b to treat Friedreich's ataxia. Horizon expects to begin a Phase III trial …

    Published on 4/10/2015
  • COMPANY NEWS: Medicines Co. projects lower Angiomax revenues

    The Medicines Co. (NASDAQ:MDCO) said it expects a sharp decline in 1Q15 revenues due to flagging sales of anticoagulant Angiomax bivalirudin.The company expects total worldwide revenues of $125-$130 million in 1Q15, …

    Published on 4/10/2015
  • COMPANY NEWS: Eisai to cut 25% of U.S. workforce

    Eisai Inc., the U.S. subsidiary of Eisai Co. Ltd. (Tokyo:4523), plans to cut about 25% of its 1,700-person workforce as part of a restructuring. Spokesperson Suzanne Grogan said the changes, effective May 1, will occur …

    Published on 4/9/2015
  • COMPANY NEWS: Management tracks

    CNS company Axsome Therapeutics Inc. (New York, N.Y.) named Randall Kaye CMO. Kay was CMO and SVP of clinical research and medical affairs at Avanir Pharmaceuticals Inc., which was acquired by Otsuka Pharmaceutical Co. …

    Published on 4/9/2015
  • COMPANY NEWS: Santhera's rise continues with Fast Track in DMD

    Santhera Pharmaceuticals Holding AG (SIX:SANN) gained CHF16.95 (18%) to CHF110.50 on Thursday after FDA granted Fast Track designation to Catena idebenone to treat Duchenne muscular dystrophy (DMD). The company intends …

    Published on 4/9/2015
  • COMPANY NEWS: Management tracks

    CRISPR Therapeutics AG (Basel, Switzerland) hired Bill Lundberg as CSO and said he will lead the creation of the company's new R&D operations in Cambridge, Mass. Lundberg was VP and head of translational medicine at …

    Published on 4/8/2015
  • COMPANY NEWS: Merck HCV combo regains breakthrough in smaller population

    Merck & Co. Inc. (NYSE:MRK) said FDA granted grazoprevir/elbasvir (MK-5172/MK-8742) breakthrough therapy designations to treat HCV genotype 4 infection and HCV genotype 1 infection in patients with end stage renal …

    Published on 4/8/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993